Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HEXA | P06865 | 2/20 | 0.43 |
| ▸ | HEXB | P07686 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342306 | 0.86 | GHSR (0.54) | GHSRNCOA1NCOA3HEXAHEXB | |
| Hydrochloric Acid SCHEMBL6353018 | 0.85 | GHSR (0.53) | GHSRNCOA1NCOA3HEXAHEXB | |
| SCHEMBL6344289 | 0.81 | GHSR (0.59) | GHSRMAPT | |
| SCHEMBL6244594 | 0.79 | GHSR (0.76) | GHSRNCOA1NCOA3CYP3A4HEXA | |
| SCHEMBL6339577 | 0.79 | GHSR (0.58) | GHSR | |
| SCHEMBL4841496 | 0.76 | DHFR (0.61) | HEXAHEXB | |
| SCHEMBL6245854 | 0.72 | GHSR (0.59) | GHSRNCOA1NCOA3CYP3A4CYP2D6 | |
| SCHEMBL1350027 | 0.72 | MAPT (0.57) | MAPT | |
| SCHEMBL6243748 | 0.71 | GHSR (0.81) | GHSR | |
| SCHEMBL14813146 | 0.71 | CYP1A2 (0.61) | GHSRNCOA1NCOA3CYP3A4HEXA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | GHSR 1/4885NCOA1 1701/4885NCOA3 2738/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | GHSR 5/4885NCOA1 1032/4885NCOA3 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.